Neurogene Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $103,845 | $136,586 |
| Short-term investments | 165,168 | 175,819 |
| Prepaid expenses and other current assets | 2,757 | 3,518 |
| Total current assets | 271,770 | 315,923 |
| Property and equipment, net | 12,792 | 15,422 |
| Operating lease right-of-use assets | 2,648 | 3,000 |
| Finance lease right-of-use assets | 22 | 71 |
| Restricted cash | 339 | 339 |
| Other non-current assets | 1,033 | 975 |
| Total assets | $288,604 | $335,730 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,953 | $1,336 |
| Accrued expenses and other current liabilities | 10,756 | 9,731 |
| Operating lease liabilities, current | 3,050 | 2,945 |
| Finance lease liabilities, current | 14 | 54 |
| Contingent value rights liability, current | 638 | 1,091 |
| Total current liabilities | 16,411 | 15,157 |
| Operating lease liabilities, non-current | 6,822 | 9,403 |
| Finance lease liabilities, non-current | 5 | 26 |
| Contingent value rights liability, non-current | 428 | 718 |
| Other liabilities | 51 | 51 |
| Total liabilities | 23,717 | 25,355 |
| Stockholders' equity | ||
| Preferred stock, $0.000001 par value; 50,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 15,489,800 and 14,854,725 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 617,536 | 572,673 |
| Accumulated deficit | (352,649) | (262,298) |
| Total stockholders' equity | 264,887 | 310,375 |
| Total liabilities and stockholders' equity | $288,604 | $335,730 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.